Cel-Sci (CVM) Stock Forecast: StockMap's 2-Week Call
CVM stock forecast: StockMap's model leans Underperform on Cel-Sci for the two weeks after the Nov 19 close, toward CVM trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 6 two-week windows on CVM since Aug 21; by chance, a call on the same dates was right 58% of the time.
Cel-Sci last closed at $1.47, +6.52% on the session.
Against the IVW growth benchmark the position is +8.85% over the forecast window.
Cel-Sci's market cap is $25.86M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -39 (too close to call).
Where CVM sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
45 daily calls for CVM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Cel-Sci in the 5th percentile on return on equity, where 100 is best.
Cel-Sci is classified under Health Care / Biotechnology.
StockMap tracks Cel-Sci as the 334th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Cel-Sci ranks 292nd of 394 in the group, against a group median of -0.27.